Subscribe

Keytruda Indicated for BCG-Unresponsive High-Risk, Non–Muscle Invasive Bladder Cancer

February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology - Drug Updates, FDA Approvals

On January 8, 2020, the FDA accelerated the approval of a new indi­cation for pembrolizumab (Keytruda; Merck & Co) for the treatment of Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk, non–muscle invasive bladder cancer and carcinoma in situ, with or without papillary tumors, in patients who are ineligible for or who have elected not to undergo cystectomy. Pembrolizumab has been previously approved for many indications.

The approval was based on efficacy results from the KEYNOTE-057 clinical trial, a multicenter, single-arm study involving 148 patients with high-risk non–muscle invasive bladder cancer, of whom 96 had BCG-­unresponsive carcinoma in situ with or without papillary tumors. Patients received pembrolizumab 200 mg every 3 weeks until unacceptable toxicity, persistent or recurrent high-risk disease, or progressive disease, or up to 24 months of therapy without disease progression.

The major efficacy outcomes were complete response, urine cytology, computed tomography urography, and duration of response. The complete response rate in the 96 patients with high-risk BCG-unresponsive disease with carcinoma in situ was 41% (95% confidence interval, 31-51), and the median response duration was 16.2 months. Overall, 46% of responding patients had a complete response lasting ≥12 months.

The most common (≥10%) adverse reactions with pembrolizumab in this study were fatigue, diarrhea, rash, pruritis, musculoskeletal pain, hematuria, cough, arthralgia, nausea, constipation, urinary tract infection, peripheral edema, hypothyroidism, and nasopharyngitis.

Related Items
Jemperli First FDA-Approved Immunotherapy for Advanced Endometrial Cancer with dMMR Biomarker
Web Exclusives published on June 16, 2021 in FDA Approvals
Rybrevant First FDA-Approved Therapy for NSCLC with EGFR Exon 20 Insertion Mutations
Web Exclusives published on June 16, 2021 in FDA Approvals
Lumakras First FDA-Approved Therapy for Advanced or Metastatic NSCLC with KRAS G12C Mutation
Web Exclusives published on June 16, 2021 in FDA Approvals
Zynlonta First FDA-Approved CD19-Directed Therapy for Large B-Cell Lymphoma
Web Exclusives published on June 16, 2021 in FDA Approvals
Cosela First CDK4/6 Inhibitor FDA Approved to Reduce Chemotherapy-Induced Myelosuppression
Web Exclusives published on May 17, 2021 in FDA Approvals
Last modified: July 6, 2021
Copyright © Engage Healthcare Communications, LLC. All rights reserved.